Acute Response to Recombinant Insulin-like Growth Factor I in a Patient with Mendenhall's Syndrome

Authors:
  • JQJ D Quin
    J D Quin
  • BFB M Fisher
    B M Fisher
  • KPK R Paterson
    K R Paterson
  • AIA Inoue
    A Inoue
  • GBG H Beastall
    G H Beastall
  • AMA C MacCuish
    A C MacCuish

Abstract
Insulin-like growth factor I (IGF-I) is a homologue of proinsulin, and its intravenous administration has been studied in normal subjects.1 It possesses approximately 6 percent of the hypoglycemic effect of insulin, and its cellular receptor is different from that for insulin.2 The potential pharmacologic effects of this hormone have not previously been studied in diabetes mellitus.

This publication has 8 references indexed in Scilit: